Immunobiology of Ebola and Lassa virus infections

被引:81
|
作者
Prescott, Joseph B. [1 ]
Marzi, Andrea [1 ]
Safronetz, David [2 ,3 ]
Robertson, Shelly J. [1 ]
Feldmann, Heinz [1 ,3 ]
Best, Sonja M. [1 ]
机构
[1] NIAID, Virol Lab, Rocky Mt Labs, NIH, 903 S Fourth St, Hamilton, MT 59840 USA
[2] Publ Hlth Agcy Canada, Zoonot Dis & Special Pathogens, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada
[3] Univ Manitoba, Dept Med Microbiol, 745 Bannatyne Ave, Winnipeg, MB R3E 0J9, Canada
基金
美国国家卫生研究院;
关键词
HUMAN DENDRITIC CELLS; DOUBLE-STRANDED-RNA; HEMORRHAGIC-FEVER; VP35; PROTEIN; IMMUNE-RESPONSES; WEST-AFRICA; INTERFERON ANTAGONISM; NONHUMAN-PRIMATES; ANIMAL-MODELS; DISEASE;
D O I
10.1038/nri.2016.138
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two of the most important contemporary emerging viruses that affect human health in Africa are Ebola virus (EBOV) and Lassa virus (LASV). The 2013-2016 West African outbreak of EBOV was responsible for more than 11,000 deaths, primarily in Guinea, Sierra Leone and Liberia. LASV is constantly emerging in these and surrounding West African countries, with an estimate of more than 500,000 cases of Lassa fever, and approximately 5,000 deaths, annually. Both EBOV and LASV are zoonotic, and human infection often results in a severe haemorrhagic fever in both cases. However, the contribution of specific immune responses to disease differs between EBOV and LASV. This Review examines innate and adaptive immune responses to these viruses with the goal of delineating responses that are associated with protective versus pathogenic outcomes.
引用
收藏
页码:195 / 207
页数:13
相关论文
共 50 条
  • [31] How to treat Ebola virus infections? A lesson from the field
    Duraffour, Sophie
    Malvy, Denis
    Sissoko, Daouda
    CURRENT OPINION IN VIROLOGY, 2017, 24 : 9 - 15
  • [32] Post-exposure treatments for Ebola and Marburg virus infections
    Robert W. Cross
    Chad E. Mire
    Heinz Feldmann
    Thomas W. Geisbert
    Nature Reviews Drug Discovery, 2018, 17 : 413 - 434
  • [33] WHAT HAS EBOLA VIRUS TO DO WITH SEXUALLY TRANSMITTED INFECTIONS?
    Low, Nicola
    SEXUALLY TRANSMITTED INFECTIONS, 2015, 91 : A11 - A11
  • [34] Post-exposure treatments for Ebola and Marburg virus infections
    Cross, Robert W.
    Mire, Chad E.
    Feldmann, Heinz
    Geisbert, Thomas W.
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (06) : 413 - 434
  • [35] Ebola and Lassa fever: Lessons learned, continuing challenges
    Garry, Robert
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 : 45 - 45
  • [36] Viral Hemorrhagic Fevers Other than Ebola and Lassa
    Lannetta, Marco
    Di Caro, Antonino
    Nicastri, Emanuele
    Vairo, Francesco
    Masanja, Honorati
    Kobinger, Gary
    Mirazimi, All
    Ntoumi, Francine
    Zumla, Alimuddin
    Ippolito, Giuseppe
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2019, 33 (04) : 977 - +
  • [37] Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa
    Emmerich, Petra
    Thome-Bolduan, Corinna
    Drosten, Christian
    Gunther, Stephan
    Ban, Eniko
    Sawinsky, Imke
    Schmitz, Herbert
    JOURNAL OF CLINICAL VIROLOGY, 2006, 37 (04) : 277 - 281
  • [38] Immunobiology of mycobacterial infections in marsupials
    Buddle, BM
    Young, LJ
    DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2000, 24 (05): : 517 - 529
  • [39] POTENTIAL DISTRIBUTION OF EBOLA, MARBURG, AND LASSA VIRUSES IN AFRICA
    Samy, Abdallah M.
    Elaagip, Arwa
    Abd El Wahed, Ahmed
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 93 (04): : 56 - 57
  • [40] Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
    Günther, S
    Asper, M
    Röser, C
    Luna, LKS
    Drosten, C
    Becker-Ziaja, B
    Borowski, P
    Chen, HM
    Hosmane, RS
    ANTIVIRAL RESEARCH, 2004, 63 (03) : 209 - 215